




## Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023

January 3, 2023

AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](#) (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12<sup>th</sup> Annual LifeSci Partners Corporate Access Event held in San Francisco January 9-11, 2023. Lumos Pharma will host in-person one-on-one meetings with the investment and biopharmaceutical community on Tuesday and Wednesday, January 10<sup>th</sup> and 11<sup>th</sup>, during the event.



Register for in-person meetings with Lumos Pharma, January 10-11, 2023, through link below

[LifeSci Partners 2023 Corporate Access Event](#)

To speak with Lumos Pharma management before or after the event, please contact Lumos Pharma investor relations.

### About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowthH210 Trial, a PK/PD trial, the OraGrowthH212 Trial, and a switch trial, the OraGrowthH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller  
Lumos Pharma Investor Relations  
512-792-5454  
[ir@lumos-pharma.com](mailto:ir@lumos-pharma.com)

Source: Lumos Pharma, Inc.

A photo accompanying this announcement is available at <https://www.globenewswire.com/NewsRoom/AttachmentNg/03eac5ac-72da-4d1b-b5aa-1c57e7add5c5>



Source: Lumos Pharma, Inc.

12th Annual Corporate Access Event



Register for in-person meetings with Lumos Pharma